IGF-1 LR3

IGF-1 LR3 is a modified form of insulin-like growth factor-1 (IGF-1) with changes that extend its half-life and alter binding to IGF-binding proteins.

It is often discussed in experimental growth factor and performance-related contexts rather than standard endocrine care.

IGF-1 receptor activation influences growth, cellular proliferation, and metabolic pathways. The LR3 modification is intended to prolong activity and modify tissue distribution.

While IGF-1 biology is central to growth and metabolism, IGF-1 LR3 itself is not a standard therapeutic agent in most guidelines.

Non-regulated use raises concerns about safety, fairness in sport, and departure from evidence-based practice.

IGF-1 LR3 is covered by sub-section S2.3 of the WADA Prohibited List, "Growth factors and growth factor modulators." The relevant bullet reads "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues," and Long R3 IGF-1 is an analogue of IGF-1 by construction. It belongs to the engineered family — "LongR3 IGF-I, Des1-3 IGF-I and Arg3 IGF-I" — designed for "their lower affinity for the IGFBPs, while still retaining unaffected affinity for the IGF-I receptor" (Adams et al., Am J Rhinol 2006). The same sub-section covers mechano growth factors, thymosin-β4 and its derivatives such as TB-500, and closes with a functional catch-all: "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." Every S2 substance is a non-Specified Substance, so the default first-violation sanction is four years.

Anti-doping analysts treat this as settled. Mongongu and colleagues open their method paper with the flat statement that "Insulin-like growth factor-I (IGF-I) and its analogs LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I are prohibited substances in sport," adding that "although they were never approved for use in humans, they are readily available as black market products for bodybuilding" (Mongongu et al., Drug Test Anal 2021). "Not an approved drug" is not a gap in the rules — it is the reason the compound is on the list.

Detection, and a counter-intuitive result. Laboratories do not try to catch LR3 by watching total IGF-1 levels, because endogenous IGF-1 is present in enormous excess. They target the analogue molecule itself. Thomas and colleagues showed that "the usage of a specific antibody for LongR3-IGF-I enables the determination in low ng/mL levels despite the presence of an enormous excess of endogenous human IGF-I," validating a magnetic-bead immunoaffinity nanoLC-HRMS plasma method with a limit of detection of 0.5 ng/mL (Thomas et al., Growth Horm IGF Res 2017).

The counter-intuitive part concerns the metabolites. In the rat administration work, intact LR3 cleared fastest of the three analogues — "LongR3-IGF-I disappeared rapidly after 4 h" following a single intramuscular dose, against 24 hours for unchanged Des(1-3)-IGF-I and R3-IGF-I — but its N-terminally truncated degradation products persisted, with Des(1-11)-LongR3-IGF-I "detected up to 16 h" (Mongongu 2021). Thomas's group reported the same principle, finding that (Des1-11)-LongR3-IGF-I "prolonged the detectability in-vivo by a factor of approximately 2." The long-acting modification that makes LR3 attractive in gray-market marketing is exactly what leaves a distinctive analytical fingerprint behind after the parent peptide is gone.

Product quality compounds the risk. Analysing black-market vials, Mongongu's group found "abundant signs of lower quality, oxidized peptide forms," which "justif[ied] the need to monitor at least both the native and mono-oxidized forms." Degraded material is not less prohibited; it simply adds analytical targets.

A Cologne doping-control laboratory case report goes further. Examining an injection vial sold as LR3, the analysts characterised the contents as "Long-R³-IGF-I with a His₆-tag attached to the C-terminus by the linker amino acids Leu-Glu" — a purification tag that belongs on a reagent protein, not an injectable. They concluded the material "may rather be a by-product from biochemical studies than synthesized for injection purposes," and noted that "the effects of His-tagged Long-R³-IGF-I in humans have not been elucidated or described" (Kohler et al., Growth Horm IGF Res 2010). An athlete injecting that vial would have taken an uncharacterised protein and still committed a violation.

A named sanction illustrates the enforcement route. Vahe Aivazian, a masters cyclist, accepted a four-year USADA sanction beginning 7 April 2021 for possessing and using ten prohibited substances including IGF-1, alongside somatropin, ipamorelin, CJC-1295, GHRP-6 and hCG (USADA sanction announcement). The violation was possession and use — no analytical finding was required.

Safety data for IGF-1 LR3 specifically are limited, and unsupervised use is associated with significant uncertainty.

IGF-1 LR3 is a long-acting analogue (half-life ~20-30 hours) that avoids binding proteins, making it much more potent than generic IGF-1.

Warning: High doses can cause hypoglycemia. Always ensure adequate carbohydrate intake around administration.

IGF-1 LR3 is supplied as a lyophilized powder for reconstitution and sold as a research reagent rather than a pharmaceutical preparation, so identity, purity, and actual peptide content are unverified. Its legitimate commercial use is as a binding-protein-resistant growth supplement in mammalian cell culture, where the absence of IGFBPs in media makes long-acting analogs stable and useful — a reagent property, not a therapeutic one.

Two combinations recur in performance discussion, and both compound the same hazard. Pairing LR3 with insulin stacks two glucose-lowering signals with different time courses, and the animal data show binding-resistant IGF variants producing roughly 4- to 8-fold greater cumulative hypoglycemia than native IGF-1 over four hours (PMID 9415072). Pairing it with somatropin adds a hormone that itself raises endogenous IGF-1, on top of an analog engineered to escape the regulation that normally constrains it.

Published work focuses on basic receptor pharmacology and limited clinical or quasi-clinical use, often outside large randomized trials.

For deeper dives on this peptide, see:

• IGF-1 LR3 benefits and areas of interest
• IGF-1 LR3 side effects and safety context
• IGF-1 LR3 dosing concepts (educational)
• IGF-1 LR3 research and evidence overview

What does the "LR3" in IGF-1 LR3 mean? Two engineered changes: arginine substituted for glutamate at position 3, and a 13-residue N-terminal extension. Both exist to reduce binding to the IGF-binding proteins that normally hold most circulating IGF-1 inactive. The result is more free peptide, acting for longer.

Is there an approved IGF-1 medicine? Yes, but it is a different molecule. Mecasermin (Increlex) is recombinant human IGF-1, approved in the US in 2005 and the EU in 2007 (PMID 19707272), indicated for growth failure in children two and older with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH. Its label states it is not a substitute for GH in approved GH indications (DailyMed). IGF-1 LR3 is not that drug and has no approval anywhere.

What was actually measured when LR3 was studied? Glucose. In pigs and marmoset monkeys, binding-resistant IGF variants including LR3IGF-I were 2- to 3-fold more potent than native IGF-I at lowering plasma glucose and produced roughly 4- to 8-fold greater cumulative hypoglycemia over four hours. Notably, the prolonged suppression was not proportional to the depth of the drop — at doses matched for equal nadir, the variants still produced about twice the cumulative effect (PMID 9415072).

Does it build muscle in humans? No controlled human trial has tested that. The claim extrapolates from IGF-1 receptor biology and from animal glucose studies. The one anabolic-adjacent finding in the primary literature is that LR3IGF-I produced a dose-related reduction in plasma amino acids — plasma chemistry, not measured muscle mass or strength.

How does it compare to IGF-DES? They were engineered toward opposite goals. LR3 is long-acting and systemic; DES(1-3)IGF-I is a truncation that is more potent still but acts briefly. In the same animal comparison, hypoglycemic potency ranked IGF-I < long-IGF-I < R3IGF-I ≈ LR3IGF-I < des(1-3)IGF-I.